Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

NCT01059526 · clinicaltrials.gov ↗

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG: ecallantide

Sponsor

Shire